Skip to content

US · AEMD · MEDICAL - DEVICES

Aethlon Medical, Inc. (AEMD) intrinsic value and stock valuation

$5.46as of 2026-11-21 · Mkt cap 1.66M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aethlon Medical, Inc. DCF and intrinsic value

InvestorsCraft values AEMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AEMD’s statements →

Aethlon Medical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices San Diego, CA 92121 aethlonmedical.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$0.00
20122026
Net income
-$-7.15M
20122026
Free cash flow
-$-7T
20122026
Total equity
$4.89M-12% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$570K$290K
Operating income-$-7.29M-$-9.34M-$-12.64M-$-11.9M-$-10.42M
Net income-$-7.15M-$-13.39M-$-12.21M-$-12.03M-$-10.42M
EPSd-$-10.67M-$-83.69M-$-407M-$-401M-$-521M
Operating cash flow-$-7T-$-7.65M-$-10.13M-$-10.51M-$-9.77M
Capital expenditure-$-3.7B$0.00-$-250K-$-940K-$-350K
Free cash flow-$-7T-$-7.65M-$-10.38M-$-11.45M-$-10.12M
Total assets$6.33M$7.36M$8.25M$17.5M$19.4M
Total debt$340K$650K$940K$1.21M$730K
Net debt-$-4.69M-$-4.85M-$-4.5M-$-13.32M-$-16.34M
Total equity$4.89M$5.12M$5.77M$15.1M$17M
Cash and short-term investments$5.03M$5.5M$5.44M$14.5M$17.1M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$570K$290K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$570K$290K
Research and development expenses$1.91M$2.21M$2.52M$2.75M$2.34M
Selling, general and administrative expenses$7.29M$9.34M$12.6M$12.5M$10.7M
Other expenses-$-1.91M-$-2.21M-$-2.52M-$-2.75M-$-2.34M
Operating expenses$7.29M$9.34M$12.6M$12.5M$10.7M
Cost and expenses$7.29M$9.34M$12.6M$12.5M$10.7M
Interest income$160K$300K$430K$10K$0.00
Interest expense$10K$10K$0.00$0.00$0.00
Depreciation and amortization$320K$340K$360K$240K$120K
Ebitda-$-6.81M-$-13.04M-$-11.85M-$-11.79M-$-10.3M
Operating income-$-7.29M-$-9.34M-$-12.64M-$-11.9M-$-10.42M
Total other income/expenses, net$140K-$-4.05M$430K-$-130K$0.00
Income before tax-$-7.15M-$-13.39M-$-12.21M-$-12.03M-$-10.42M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.15M-$-13.39M-$-12.21M-$-12.03M-$-10.42M
Weighted average shares outstanding$670K$160K$30K$30K$20K
Weighted average diluted shares outstanding$670K$160K$30K$30K$20K
Balance sheet
20262025202420232022
Cash and short-term investments$5.03M$5.5M$5.44M$14.5M$17.1M
Net receivables$0.00$0.00$0.00$0.00$130K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.57M$5.95M$6.23M$15.1M$18.2M
Property, plant and equipment, net$660K$1.28M$1.9M$2.3M$1.14M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$100K$90K$90K$90K
Total non-current assets$760K$1.41M$2.02M$2.42M$1.26M
Total assets$6.33M$7.36M$8.25M$17.5M$19.4M
Accounts payable$380K$530K$780K$430K$500K
Short-term debt$340K$310K$290K$270K$130K
Deferred revenue$0.00$0.00$0.00$0.00$340K
Total current liabilities$1.45M$1.9M$1.83M$1.51M$1.82M
Long-term debt$0.00$340K$650K$940K$600K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$340K$650K$940K$600K
Capital lease obligations$340K$650K$940K$1.21M$730K
Total liabilities$1.45M$2.24M$2.48M$2.44M$2.43M
Common stock$0.00$0.00$0.00$20K$20K
Retained earnings-$-175.11M-$-167.95M-$-154.57M-$-142.36M-$-130.33M
Accumulated other comprehensive income (loss)-$-30K-$-20K-$-10K-$-10K$0.00
Total equity$4.89M$5.12M$5.77M$15.1M$17M
Total investments$0.00$100K$90K$90K$90K
Total debt$340K$650K$940K$1.21M$730K
Net debt-$-4.69M-$-4.85M-$-4.5M-$-13.32M-$-16.34M
Cash flow statement
20262025202420232022
Net income-$-7.15T-$-13.39M-$-12.21M-$-12.03M-$-10.42M
Depreciation and amortization$323.7B$340K$360K$240K$120K
Stock-based compensation$278.5B$420K$1.22M$1.05M$750K
Change in working capital-$-740K$90K$480K$70K-$-250K
Accounts receivable$0.00$0.00$0.00$130K$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-380K-$-50K$160K-$-170K$100K
Net cash provided by operating activities-$-7T-$-7.65M-$-10.13M-$-10.51M-$-9.77M
Investments in property, plant and equipment-$-3.7B$0.00-$-250K-$-940K-$-350K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-3.7B$0.00-$-250K-$-940K-$-350K
Common stock issued$6.66M$3.54M$1.32M$8.93M$17.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.52T$7.73M$1.29M$8.91M$17.4M
Net change in cash-$-473.69B$70K-$-9.09M-$-2.54M$7.25M
Cash at end of period$5.13T$5.6M$5.53M$14.6M$17.2M
Operating cash flow-$-7T-$-7.65M-$-10.13M-$-10.51M-$-9.77M
Capital expenditure-$-3.7B$0.00-$-250K-$-940K-$-350K
Free cash flow-$-7T-$-7.65M-$-10.38M-$-11.45M-$-10.12M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aethlon Medical, Inc.

        Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.

        CEO
        James Frakes
        Employees
        9
        Beta
        1.41

        Explore

        Frequently asked questions

        What is the intrinsic value of Aethlon Medical, Inc. (AEMD)?

        InvestorsCraft does not currently publish an intrinsic value for AEMD. How the IC value is calculated.

        Is AEMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for AEMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.